 |
市場調査レポート
商品コード
1110387
インスリンの世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）Insulin Market (Mode of Action: Rapid-acting, Short-acting, Intermediate-acting, Premixed, and Long-acting; and Source: Modern Insulin and Human Insulin) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| インスリンの世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年） |
|
出版日: 2022年06月14日
発行: Transparency Market Research
ページ情報: 英文 160 Pages
納期: 2～10営業日
|
- 全表示
- 概要
- 図表
- 目次
概要
当レポートでは、世界のインスリン市場について調査分析し、市場動向、セグメント分析、地域分析、企業プロファイルなどを提供しています。
目次
第1章 序文
第2章 前提条件と調査手法
第3章 エグゼクティブサマリー：世界のインスリン市場
第4章 市場概要
- イントロダクション
- 定義
- 業界の進化/発展
- 概要
- 市場力学
- 促進要因
- 抑制要因
- 機会
- 世界のインスリン市場分析と予測（2017年～2031年）
第5章 主要洞察
- 規制シナリオ：地域別/世界
- 主要な合併と買収
- 技術進歩
- COVID-19パンデミックが業界に与える影響
第6章 世界のインスリン市場分析と予測：作用機序別
- イントロダクションと定義
- 主要な調査結果/発展
- 市場価値予測（2017年～2031年）：作用機序別
- 超即効型
- 即効型
- 中間型
- 混合型
- 時効型
- 市場の魅力分析：作用機序別
第7章 世界のインスリン市場分析と予測：ソース別
- イントロダクションと定義
- 主要な調査結果/発展
- 市場価値予測（2017年～2031年）：ソース別
- インスリンアナログ
- ヒトインスリン
- 市場の魅力分析：ソース別
第8章 世界のインスリン市場分析と予測：地域別
- 主要な調査結果
- 市場価値予測：地域別
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
- 市場の魅力分析：地域別
第9章 北米のインスリン市場分析と予測
- イントロダクション
- 主要な調査結果
- 市場価値予測（2017年～2031年）：作用機序別
- 超即効型
- 即効型
- 中間型
- 混合型
- 時効型
- 市場価値予測（2017年～2031年）：ソース別
- インスリンアナログ
- ヒトインスリン
- 市場価値予測（2017年～2031年）：国別
- 米国
- カナダ
- 市場の魅力分析
- 作用機序別
- ソース別
- 国別
第10章 欧州のインスリン市場分析と予測
第11章 アジア太平洋のインスリン市場分析と予測
第12章 ラテンアメリカのインスリン市場分析と予測
第13章 中東・アフリカのインスリン市場分析と予測
第14章 競合情勢
- 市場企業 - 競合マトリクス（階層・企業規模別）
- 市場シェア分析（2021年）：企業別
- 企業プロファイル
- Shanghai Fosun Pharmaceutical Co., Ltd.
- Tonghua Dongbao
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- Julphar
- Biocon Ltd.
- Becton, Dickinson and Company
- Ypsomed AG
- Biodel Inc.
- B. Braun Melsungen AG
図表
List of Tables
- Table 1: Market Snapshot: Global Insulin Market
- Table 2: Global Prevalence of Diabetes, by Type
- Table 3: Global Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
- Table 4: Global Insulin Market Revenue (US$ Mn), by Source, 2017-2031
- Table 5: Global Insulin Market Revenue (US$ Mn), by Region, 2017-2031
- Table 6: North America Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
- Table 7: Europe Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
- Table 8: Asia Pacific Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
- Table 9: Latin America Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
- Table 10: Middle East & Africa Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
List of Figures
- Figure 1: Insulin: Market Segmentation
- Figure 2: Global Insulin Market Revenue (US$ Mn), by Mode of Action, 2021
- Figure 3: China Insulin Market Revenue (US$ Mn), by Mode of Action, 2021
- Figure 4: Value Chain: Global Insulin Market
- Figure 5: Porter's Five Forces Analysis: Global Insulin Market
- Figure 6: Market Attractiveness Analysis: Global Insulin Market, by Mode of Action
- Figure 7: Comparative Analysis: Global Insulin Market Revenue (US$ Mn), by Mode of Action 2021 & 2031
- Figure 8: Global Short-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 9: Global Short-Acting Insulin Market Volume (tMU), 2017 - 2031
- Figure 10: Global Rapid-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 11: Global Rapid-Acting Insulin Market Volume (tMU), 2017 - 2031
- Figure 12: Global Afrezza Market Revenue (US$ Mn), 2017 - 2031
- Figure 13: Global NN1218 Market Revenue (US$ Mn), 2017 - 2031
- Figure 14: Global Long-Acting Insulin Market Revenue, 2017 - 2031
- Figure 15: Global Long-Acting Insulin Market Volume (tMU), 2017 - 2031
- Figure 16: Global LY2605541 Market Revenue (US$ Mn), 2017 - 2031
- Figure 17: Global LY2963016 Market Revenue (US$ Mn), 2017 - 2031
- Figure 18: Global MK-1293 Market Revenue (US$ Mn), 2017 - 2031
- Figure 19: Global U-300 Market Revenue (US$ Mn), 2017 - 2031
- Figure 20: Global IDegLira Market Revenue (US$ Mn), 2017 - 2031
- Figure 21: Global Intermediate-acting Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 22: Global Intermediate-acting Insulin Market Volume (tMU), 2017 - 2031
- Figure 23: Global Premixed Market Revenue (US$ Mn), 2017 - 2031
- Figure 24: Global Premixed Insulin Market Volume (tMU), 2017 - 2031
- Figure 25: Breakdown of insulin-dependent population in China (2009)
- Figure 26: China Short-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 27: China Short-Acting Insulin Market Volume (tMU), 2017 - 2031
- Figure 28: China Rapid-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 29: China Rapid-Acting Insulin Market Volume (tMU), 2017 - 2031
- Figure 30: China Long-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 31: China Long-Acting Insulin Market Volume (tMU), 2017 - 2031
- Figure 32: China Intermediate-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 33: China Intermediate-Acting Insulin Market Volume (tMU), 2017 - 2031
- Figure 34: China Premixed Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 35: China Premixed Insulin Market Volume (tMU), 2017 - 2031
- Figure 36: Global Human Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 37: Global Human Insulin Market Volume (tMU), 2017 - 2031
- Figure 38: Global Modern Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 39: Global Modern Insulin Market Volume (tMU), 2017 - 2031
- Figure 40: China Human Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 41: China Human Insulin Market Volume (tMU), 2017 - 2031
- Figure 42: China Modern Insulin Market Revenue (US$ Mn), 2017 - 2031
- Figure 43: China Modern Insulin Market Volume (tMU), 2017 - 2031
- Figure 44: Global Insulin Market Share Analysis, by Key Players, 2021 (%)
- Figure 45: Global Insulin Market Share Analysis, by Key Players, 2021 (%)
- Figure 46: Eli Lilly and Company: Annual Revenue (US$ Mn), 2017 - 2031
- Figure 47: Novo Nordisk A/S.: Annual Revenue (US$ Mn), 2017 - 2031
- Figure 48: Sanofi: Annual Revenue (US$ Mn), 2017 - 2031
- Figure 49: Shanghai Fosun Pharmaceutical Co., Ltd.: Annual Revenue (US$ Mn), 2017 - 2031
目次
Product Code: TMRGL259
The report provides revenue of the global insulin market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global insulin market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the insulin market.
The report delves into the competitive landscape of the global insulin market. Key players operating in the global insulin market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global insulin market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Insulin Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Insulin Market Analysis and Forecast, 2017-2031
5. Key Insights
- 5.1. Regulatory Scenario, by Region/globally
- 5.2. Key Mergers & Acquisitions
- 5.3. Technological Advancements
- 5.4. COVID-19 Pandemics Impact on Industry
6. Global Insulin Market Analysis and Forecast, by Mode of Action
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Mode of Action, 2017-2031
- 6.3.1. Rapid-acting
- 6.3.2. Short-acting
- 6.3.3. Intermediate-acting
- 6.3.4. Premixed
- 6.3.5. Long-acting
- 6.4. Market Attractiveness Analysis, by Mode of Action
7. Global Insulin market Analysis and Forecast, by Source
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Source, 2017-2031
- 7.3.1. Modern Insulin
- 7.3.2. Human Insulin
- 7.4. Market Attractiveness Analysis, by Source
8. Global Insulin market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Market Value Forecast, by Region
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Market Attractiveness Analysis, by Region
9. North America Insulin Market Analysis and Forecast
- 9.1. Introduction
- 9.1.1. Key Findings
- 9.2. Market Value Forecast, by Mode of Action, 2017-2031
- 9.2.1. Rapid-acting
- 9.2.2. Short-acting
- 9.2.3. Intermediate-acting
- 9.2.4. Premixed
- 9.2.5. Long-acting
- 9.3. Market Value Forecast, by Source, 2017-2031
- 9.3.1. Modern Insulin
- 9.3.2. Human Insulin
- 9.4. Market Value Forecast, by Country, 2017-2031
- 9.4.1. U.S.
- 9.4.2. Canada
- 9.5. Market Attractiveness Analysis
- 9.5.1. By Mode of Action
- 9.5.2. By Source
- 9.5.3. By Country
10. Europe Insulin Market Analysis and Forecast
- 10.1. Introduction
- 10.1.1. Key Findings
- 10.2. Market Value Forecast, by Mode of Action, 2017-2031
- 10.2.1. Rapid-acting
- 10.2.2. Short-acting
- 10.2.3. Intermediate-acting
- 10.2.4. Premixed
- 10.2.5. Long-acting
- 10.3. Market Value Forecast, by Source, 2017-2031
- 10.3.1. Modern Insulin
- 10.3.2. Human Insulin
- 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 10.4.1. Germany
- 10.4.2. U.K.
- 10.4.3. France
- 10.4.4. Italy
- 10.4.5. Spain
- 10.4.6. Rest of Europe
- 10.5. Market Attractiveness Analysis
- 10.5.1. By Mode of Action
- 10.5.2. By Source
- 10.5.3. By Country/Sub-region
11. Asia Pacific Insulin Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Mode of Action, 2017-2031
- 11.2.1. Rapid-acting
- 11.2.2. Short-acting
- 11.2.3. Intermediate-acting
- 11.2.4. Premixed
- 11.2.5. Long-acting
- 11.3. Market Value Forecast, by Source, 2017-2031
- 11.3.1. Modern Insulin
- 11.3.2. Human Insulin
- 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.4.1. China
- 11.4.2. Japan
- 11.4.3. India
- 11.4.4. Australia & New Zealand
- 11.4.5. Rest of Asia Pacific
- 11.5. Market Attractiveness Analysis
- 11.5.1. By Mode of Action
- 11.5.2. By Source
- 11.5.3. By Country/Sub-region
12. Latin America Insulin Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Mode of Action, 2017-2031
- 12.2.1. Rapid-acting
- 12.2.2. Short-acting
- 12.2.3. Intermediate-acting
- 12.2.4. Premixed
- 12.2.5. Long-acting
- 12.3. Market Value Forecast, by Source, 2017-2031
- 12.3.1. Modern Insulin
- 12.3.2. Human Insulin
- 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Rest of Latin America
- 12.5. Market Attractiveness Analysis
- 12.5.1. By Mode of Action
- 12.5.2. By Source
- 12.5.3. By Country/Sub-region
13. Middle East & Africa Insulin Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Mode of Action, 2017-2031
- 13.2.1. Rapid-acting
- 13.2.2. Short-acting
- 13.2.3. Intermediate-acting
- 13.2.4. Premixed
- 13.2.5. Long-acting
- 13.3. Market Value Forecast, by Source, 2017-2031
- 13.3.1. Modern Insulin
- 13.3.2. Human Insulin
- 13.3.3. Infection Treatment
- 13.3.4. Gas Embolism
- 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.4.1. GCC Countries
- 13.4.2. South Africa
- 13.4.3. Rest of Middle East & Africa
- 13.5. Market Attractiveness Analysis
- 13.5.1. By Mode of Action
- 13.5.2. By Source
- 13.5.3. By Country
14. Competition Landscape
- 14.1. Market Player - Competition Matrix (by tier and size of companies)
- 14.2. Market Share Analysis, by Company, 2021
- 14.3. Company Profiles
- 14.3.1. Shanghai Fosun Pharmaceutical Co., Ltd.
- 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.1.2. Financial Analysis
- 14.3.1.3. Growth Strategies
- 14.3.1.4. SWOT Analysis
- 14.3.2. Tonghua Dongbao
- 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.2.2. Financial Analysis
- 14.3.2.3. Growth Strategies
- 14.3.2.4. SWOT Analysis
- 14.3.3. Eli Lilly and Company
- 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.3.2. Financial Analysis
- 14.3.3.3. Growth Strategies
- 14.3.3.4. SWOT Analysis
- 14.3.4. Sanofi
- 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.4.2. Financial Analysis
- 14.3.4.3. Growth Strategies
- 14.3.4.4. SWOT Analysis
- 14.3.5. Novo Nordisk A/S
- 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.5.2. Financial Analysis
- 14.3.5.3. Growth Strategies
- 14.3.5.4. SWOT Analysis
- 14.3.6. Julphar
- 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.6.2. Financial Analysis
- 14.3.6.3. Growth Strategies
- 14.3.6.4. SWOT Analysis
- 14.3.7. Biocon Ltd.
- 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.7.2. Financial Analysis
- 14.3.7.3. Growth Strategies
- 14.3.7.4. SWOT Analysis
- 14.3.8. Becton, Dickinson and Company
- 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.8.2. Financial Analysis
- 14.3.8.3. Growth Strategies
- 14.3.8.4. SWOT Analysis
- 14.3.9. Ypsomed AG
- 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.9.2. Financial Analysis
- 14.3.9.3. Growth Strategies
- 14.3.9.4. SWOT Analysis
- 14.3.10. Biodel Inc.
- 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.10.2. Financial Analysis
- 14.3.10.3. Growth Strategies
- 14.3.10.4. SWOT Analysis
- 14.3.11. B. Braun Melsungen AG
- 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.11.2. Financial Analysis
- 14.3.11.3. Growth Strategies
- 14.3.11.4. SWOT Analysis
- 14.3.1. Shanghai Fosun Pharmaceutical Co., Ltd.
